Yale School of Medicine, New Haven, CT 06510, USA.
Oncol Rep. 2021 Mar;45(3):891-898. doi: 10.3892/or.2020.7911. Epub 2020 Dec 24.
Tyrosine kinase inhibitors (TKIs) have emerged as a new frontier of cancer therapy. These agents include inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), BRAF, mitogen‑activated protein kinase kinase (also referred to as MEK), bcr‑abl, c‑KIT, platelet‑derived growth factor (PDGFR), fibroblast growth factor receptor (FGFR), anaplastic lymphoma kinase (ALK) and vascular endothelial growth factor (VEGF). Along with the evolving applications of TKIs, there has been an increased recognition of the breadth of potential cutaneous toxicities to these agents. In this review, we provide an overview of potentially life‑threatening severe cutaneous adverse reactions (SCARs) that may occur during therapy with TKIs. These toxicities include Stevens‑Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP).
酪氨酸激酶抑制剂（TKIs）已成为癌症治疗的新前沿。这些药物包括表皮生长因子受体（EGFR）、人表皮生长因子受体 2（HER2）、BRAF、丝裂原活化蛋白激酶激酶（也称为 MEK）、bcr-abl、c-KIT、血小板衍生生长因子（PDGFR）、成纤维细胞生长因子受体（FGFR）、间变性淋巴瘤激酶（ALK）和血管内皮生长因子（VEGF）的抑制剂。随着 TKI 的应用不断发展，人们越来越意识到这些药物可能会引起广泛的潜在皮肤毒性。在这篇综述中，我们概述了在使用 TKI 治疗过程中可能发生的危及生命的严重皮肤不良反应（SCARs）。这些毒性包括史蒂文斯-约翰逊综合征（SJS）、中毒性表皮坏死松解症（TEN）、药物反应伴嗜酸性粒细胞增多和全身症状（DRESS）以及急性泛发性发疹性脓疱病（AGEP）。
